Katherine A. Morgan, M.D.

Accepting New Patients
Title
  • Clinical Director, Islet Transplant Program
Degree M.D.
School Emory University School of Medicine
Residency
  • Emory University
Board Certification
  • American Board of Surgery
Specialties
  • Gastrointestinal Surgery
  • Cancer - Gastrointestinal
Clinical Interests
  • Bile duct cancer
  • Esophageal reflux
  • Biliary disease
  • Gallstones
  • Hernia surgery
  • IPMNs of the pancreas
  • Pancreas tumor
  • Pancreatic cancer
  • Pancreatitis
  • Paraesophageal hernia
Accepts New Patients Yes

Locations

MUSC Health - Nexton
5500 Front Street, Suite 320
Summerville, SC 29483
Map & Directions
Ashley River Tower
25 Courtenay Drive
Charleston, SC 29425
Map & Directions
 

Biography

Dr. Katherine Morgan was raised in Atlanta, Georgia and received her undergraduate degree with distinction from the University of Virginia in Charlottesville, Virginia in 1994. She underwent her medical education at Emory University in Atlanta, graduating summa cum laude in 1998. She went on to complete her general surgery training at Emory.

Dr. Morgan joined the faculty at the Medical University of South Carolina in 2003. Dr. Morgan is professor of surgery and chief of the Division of GI and Laparoscopic Surgery. Her special surgical interests include hepatobiliary and pancreatic surgery and minimally invasive surgery. She has particular interest in pancreas cancer, borderline resectable pancreatic cancer, neuroendocrine tumors of the pancreas, pancreatic cystic neoplasms, bile duct tumors, and gallbladder cancers. She has clinical and research interests in acute and chronic pancreatitis. In addition, she specializes in foregut disorders, specifically paraesophageal hernias, and surgical management of gastroesophageal reflux disease including laparoscopic nissen procedures and other minimally invasive approaches, including robotic surgery.

Dr. Morgan is a recognized expert nationally and internationally on pancreatic disorders. She is the institutional principal investigator on the Alliance trial evaluating the role of neoadjuvant chemotherapy in resectable pancreatic cancer.